Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 3/20 | 0.49 |
| ▸ | BMP1 | P13497 | 7/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024637 | 0.82 | BMP1 (0.48) | BMP1MMP12ALDH1A1 | |
| SCHEMBL6025275 | 0.81 | BMP1 (0.50) | BMP1MMP12 | |
| SCHEMBL6024276 | 0.80 | BMP1 (0.51) | BMP1MMP12 | |
| SCHEMBL6023832 | 0.80 | BMP1 (0.58) | BMP1MMP12 | |
| SCHEMBL6024195 | 0.79 | BMP1 (0.59) | GAABMP1MMP12LMNA | |
| SCHEMBL6024792 | 0.79 | BMP1 (0.49) | BMP1MMP12 | |
| SCHEMBL6024751 | 0.78 | BMP1 (0.48) | CCKBRBMP1MMP12 | |
| SCHEMBL6024831 | 0.78 | BMP1 (0.46) | BMP1MMP12 | |
| SCHEMBL6024103 | 0.78 | BMP1 (0.53) | BMP1MMP12 | |
| SCHEMBL6024599 | 0.78 | BMP1 (0.49) | GAABMP1MMP12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | claimed |
| EP-1363873-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | claimed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | claimed |
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1363873-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | GAA 1013/4885HPGD 2209/4885DRD2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.